磁共振成像靶向前列腺穿刺活检与系统穿刺活检在前列腺癌检测中的比较:系统评价与Meta分析
该系统评价与Meta分析纳入68项配对设计和8项随机对照试验,共14709名接受前列腺活检的男性,比较MRI靶向活检与系统活检对临床显著和临床不显著前列腺癌的检出率。结果显示MRI靶向活检检出更多临床显著癌(DR 1.16,95%CI 1.09-1.24,p<0.0001),检出更少临床不显著癌(DR 0.66,95%CI 0.57-0.76,p<0.0001),且阳性针芯比例更高(RR 3.17,95%CI 2.82-3.56,p<0.0001)。作者结论认为MRI靶向活检是系统活检的有吸引力的替代诊断策略。
要点
- MRI靶向活检较系统活检检出更多临床显著前列腺癌(DR 1.16,95%CI 1.09-1.24)。
- MRI靶向活检较系统活检检出更少临床不显著前列腺癌(DR 0.66,95%CI 0.57-0.76)。
- MRI靶向活检的阳性针芯比例高于系统活检(RR 3.17,95%CI 2.82-3.56)。
核心结论
- MRI靶向活检是系统活检的有吸引力的替代诊断策略。
研究设计与样本
- 系统评价与Meta分析,纳入68项配对设计和8项随机对照试验,共14709名接受前列腺活检以诊断前列腺癌的男性。
- 文献检索覆盖PubMed、Embase、Web of Science、Cochrane library和Clinicaltrials.gov数据库。
- 纳入前瞻性和回顾性配对研究,索引试验为MRI靶向活检,对照试验为系统活检;同时纳入一组为MRI靶向活检、另一组为系统活检的随机对照试验。
- 偏倚风险采用改良的质量评估诊断准确性研究-2清单评估,随机对照试验采用Cochrane偏倚风险2.0工具评估。
主要发现
- MRI靶向活检检出临床显著癌的比例高于系统活检(检出比1.16,95%CI 1.09-1.24,p<0.0001)。
- MRI靶向活检检出临床不显著癌的比例低于系统活检(检出比0.66,95%CI 0.57-0.76,p<0.0001)。
- MRI靶向活检的阳性针芯比例高于系统活检(相对风险3.17,95%CI 2.82-3.56,p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Magnetic resonance imaging (MRI)-targeted prostate biopsy (MRI-TB) may be an alternative to systematic biopsy for diagnosing prostate cancer. OBJECTIVE: The primary aims of this systematic review and meta-analysis were to compare the detection rates of clinically significant and clinically insignificant cancer by MRI-TB with those by systematic biopsy in men undergoing prostate biopsy to identify prostate cancer. EVIDENCE ACQUISITION: A literature search was conducted using the PubMed, Embase, Web of Science, Cochrane library, and Clinicaltrials.gov databases. We included prospective and retrospective paired studies where the index test was MRI-TB and the comparator test was systematic biopsy. We also included randomised controlled trials (RCTs) if one arm included MRI-TB and another arm included systematic biopsy. The risk of bias was assessed using a modified Quality Assessment of Diagnostic Accuracy Studies-2 checklist. In addition, the Cochrane risk of bias 2.0 tool was used for RCTs. EVIDENCE SYNTHESIS: We included 68 studies with a paired design and eight RCTs, comprising a total of 14709 men who either received both MRI-TB and systematic biopsy, or were randomised to receive one of the tests. MRI-TB detected more men with clinically significant cancer than systematic biopsy (detection ratio [DR] 1.16 [95% confidence interval {CI} 1.09-1.24], p<0.0001) and fewer men with clinically insignificant cancer than systematic biopsy (DR 0.66 [95% CI 0.57-0.76], p<0.0001). The proportion of cores positive for cancer was greater for MRI-TB than for systematic biopsy (relative risk 3.17 [95% CI 2.82-3.56], p<0.0001). CONCLUSIONS: MRI-TB is an attractive alternative diagnostic strategy to systematic biopsy. PATIENT SUMMARY: We evaluated the published literature, comparing two methods of diagnosing prostate cancer. We found that biopsies targeted to suspicious areas on magnetic resonance imaging were better at detecting prostate cancer that needs to be treated and avoiding the diagnosis of disease that does not need treatment than the traditional systematic biopsy.
引用
- Kasivisvanathan V, Stabile A, Neves JB, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019. PMID: 31130434. doi:10.1016/j.eururo.2019.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。